ArticleScientific reports2026
Validated comprehensive RP HPLC approach for separation and quantification of solifenacin and mirabegron in the presence of their degradation products.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A rapid and efficient High-Performance Liquid Chromatography (HPLC) method was developed and optimized for the separation and quantification of solifenacin succinate (SOL), mirabegron (MIR), solifenacin impurities A (SOL IMP A), I (SOL IMP I) and mirabegron metabolite (MIR MET) using a C18 column. Solifenacin succinate is a muscarinic receptor antagonist used in the treatment of overactive bladder (OAB) by reducing bladder muscle contractions, while mirabegron, a β3-adrenergic agonist, works by relaxing the bladder smooth muscle to improve storage capacity and reduce symptoms of OAB. However, the presence of impurities and metabolites, such as solifenacin impurities A, I, and E, can negatively impact the safety and efficacy of these drugs, potentially causing adverse effects such as increased toxicity, altered pharmacodynamics, or diminished therapeutic effectiveness. The method employed an isocratic elution system with a mobile phase of water containing 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B), using a C18 column (4.6 mm × 100 mm, 3 μm) at a flow rate of 1.2 mL/min and a column temperature of 30 °C. UV detection at 220 nm allowed for the efficient separation of all analytes within 10.5 min, with excellent resolution between solifenacin succinate, mirabegron, their metabolites, and impurities. The linearity range for solifenacin succinate and mirabegron was 1–100 µg/mL, and solifenacin impurities A, I, and E, and mirabegron metabolite exhibited linearity ranges of 0.1–10 and 0.1–50 µg/mL, respectively. Validation studies confirmed good precision (RSD < 2%) and accuracy, making this method suitable for routine quality control and pharmacokinetic studies. This validated HPLC method offers a reliable tool for monitoring the purity of solifenacin succinate and mirabegron, ensuring their therapeutic efficacy and safety by quantifying both the active compounds and potentially harmful impurities or metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.